BDBM652723 (S*)-4-chloro-N6-((2-((5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)methoxy)pyridin-4- yl)methyl)isoquinoline-1,6-diamine::US20240059691, Example 4438

SMILES Nc1ncc(Cl)c2cc(NCc3ccnc(OC[C@H]4CCn5ccnc5C4)c3)ccc12

InChI Key InChIKey=MABZHGPFQUEHHT-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 652723   

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 200nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 2.50E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 6.50E+3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor X(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 2.50E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 2.50E+4nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetPlasminogen(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent

TargetSerine protease 1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM652723(US20240059691, Example 4438 | (S*)-4-chloro-N6-((2...)
Affinity DataIC50: 3nMAssay Description:In vitro inhibition of related proteases was determined using an (C50 assay based on standard literature methods (see e.g. Shori et al., Biochem. Pha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
Go to US Patent